Indication*

Type 2 DM as initial therapy to improve glycemic control when diet & exercise alone do not provide adequate glycemic control. Type 2 DM as adjunct to diet & exercise to improve glycemic control in patients who can not be controlled with metformin or sitagliptin alone or in patients already being treated with combination of sitagliptin & metformin. As part of triple combination therapy with a sulfonylurea or with a PPARY agonist (ie, thiazolidinediones) as an adjunct to diet & exercise in patients with type 2 DM inadequately controlled with any 2 of 3 agents: Metformin, sitagliptin or a sulfonylurea alone or a PPARY agonist alone. Type 2 DM as an adjunct to diet & exercise to improve glycemic control in combination with insulin; sitagliptin & metformin.

Directions for Use*

Administration*

Should be taken with food.

*written indications, directions, and administration are updated as of March 05, 2024 and may not be accurate with the actual product purchased. Please read the details in the packaging.

Share

Share

Link

Close share Copy link

View full details